Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Executive summary

Conclusions

1 evidence topic · 18 sources

Summary: conclusions for formulary review
  • Regulatory status and timing: palazestrant is investigational, with no FDA-approved indication, prescribing information, or price; Olema Oncology has no product candidates “approved for commercial sale”. FDA granted Fast Track designation in July 2022 for ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. The company anticipates OPERA-01 top-line results in the first quarter of 2027, expects to submit the NDA in 2027, and anticipates potential FDA approval and commercial launch in 2028.
  • Pivotal trial: OPERA-01 (NCT06016738) is a phase 3, randomized, open-label trial that, in Part 2, compares palazestrant 90 mg once daily with investigator's choice of standard-of-care endocrine therapy (fulvestrant or an aromatase inhibitor) in participants whose disease progressed after endocrine therapy combined with a CDK4/6 inhibitor. Approximately 510 participants are planned, including 470 for the primary analysis. The dual primary endpoint is PFS by blinded independent central review, analyzed separately in participants with ESR1-mutated tumors and in participants without detectable ESR1 mutations; overall survival is a key secondary endpoint, and patient-reported outcomes (EQ-5D-5L and EORTC QLQ-C30) are secondary endpoints. Enrollment is complete, and no efficacy, safety, or patient-reported outcome results have been reported.
  • Monotherapy evidence base: all efficacy data for palazestrant monotherapy come from OP-1250-001 (NCT04505826), an open-label, multicenter phase 1/2 study without a comparator arm, a design the authors state limits interpretation of the safety profile and antitumor activity. These data were obtained with capsules taken in the fasted state, whereas OPERA-01 participants receive a tablet formulation, and only 6 participants were enrolled at the 90 mg dose selected for OPERA-01, all during dose escalation.
  • Monotherapy efficacy (OP-1250-001, peer-reviewed publication, data cutoff July 7, 2023): of the 116 participants treated at 60 or 120 mg/day, 95.7% had received a prior CDK4/6 inhibitor and 63.8% at least 2 prior lines of endocrine therapy in the advanced setting. In the 120 mg/day cohort (n = 86), 3 of 66 response-evaluable participants (4.5%) had a confirmed partial response, the CBR was 45.7% (95% CI, 33.7 to 58.1) among 70 CBR-evaluable participants and 58.6% (95% CI, 38.9 to 76.5) among 29 with ESR1 mutations, and median PFS was 4.8 months (95% CI, 3.5 to 7.1) overall and 5.6 months (95% CI, 4.8 to not estimable) with ESR1 mutations. The 60 mg/day cohort had a CBR of 19.2% (95% CI, 6.6 to 39.4) among 26 evaluable participants. The 2023 conference presentation of the 120 mg cohort reports a CBR of 40% (32/81) and a median PFS of 4.6 months.
  • Combination evidence comes from two open-label phase 1b studies: with ribociclib (OP-1250-003, July 8, 2025 data cutoff, 72 participants presented, 24 of whom (33%) had no prior line of therapy in the advanced setting), median PFS in the 120 mg cohort was 15.5 months in all participants and 12.2 months in those with a prior CDK4/6 inhibitor, the objective response rate was 34% (15/44) among response-evaluable participants with measurable disease, and median PFS was not reached in the 90 mg cohort at a median follow-up of 10.8 months. With palbociclib (OP-1250-002, September 15, 2023 data cutoff, 46 participants), the CBR was 46% (12/26).
  • Safety: in the 120 mg/day monotherapy cohort (n = 86), the most common treatment-emergent adverse events were nausea (62.8%), vomiting (29.1%), and fatigue (25.6%); 8 participants (9.3%) had grade 4 events, including neutropenia in 6, and treatment-related grade 4 neutropenia occurred in 5 (5.8%). Bradycardia (9%) and photopsia (5%) were all grade 1, no QTcF value exceeded 500 ms, and 7 of 116 participants (6.0%) at 60 or 120 mg/day discontinued for adverse events. Ongoing studies monitor blood counts more frequently during the first 6 to 8 weeks. With ribociclib at palazestrant 120 mg, treatment-related neutropenia occurred in 47 of 56 participants (84%), grade 3 in 28 (50%) and grade 4 in 5 (9%), and treatment-related QT prolongation on electrocardiogram in 16 (29%).
  • Studied population relative to approved oral endocrine agents: elacestrant, imlunestrant, and vepdegestrant are indicated for ESR1-mutated disease after at least one line of endocrine therapy, and each label directs selection of patients “based on the presence of ESR1 mutation(s)” in a plasma specimen. OPERA-01 enrolls participants “regardless of ESR1 mutation status”, and the company states that “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”. Without ESR1 mutations, the PFS hazard ratio for elacestrant was 0.86 (95% CI, 0.63 to 1.19) in an exploratory analysis of 250 participants, and median PFS was 5.6 months with imlunestrant and 5.7 months with standard therapy (hazard ratio 1.00). In OP-1250-001, 51 of 96 participants with baseline circulating tumor DNA results (53.1%) had ESR1 mutations; in the 120 mg cohort, the conference presentation reports a CBR of 32% (12/38) and the 2023 company announcement a median PFS of 3.5 months in participants with ESR1 wild-type tumors.
  • Price and economic evidence: no wholesale acquisition cost, budget impact model, or cost-effectiveness analysis of palazestrant has been published. Comparator wholesale acquisition costs are $21,369.00 per 30 tablets of elacestrant 345 mg and $22,500.00 per 56 tablets of imlunestrant 200 mg, and a U.S. third-party payer model estimated an ICER of $8,672,360 per QALY gained for elacestrant compared with standard of care in the overall population. The corporate presentation gives an annual U.S. incidence “estimated at ~40K” alongside “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”.
  • Evidence not yet available for review: OPERA-01 PFS results in the ESR1-mutated and ESR1 mutation-not-detected populations, overall survival, patient-reported outcomes, and safety with the 90 mg tablet in a randomized comparison; FDA-approved prescribing information, including the indicated population; a wholesale acquisition cost; and a budget impact or cost-effectiveness analysis of palazestrant.